All In Biotech

Drug Trial Radar · NCT04188509

Open-Label Extension of Voxelotor

An Open-Label Extension Study of Voxelotor Administered Orally to Participants With Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials

Last checked: Nov 20, 2026Latest source record: Nov 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

162

Actual

Start

Nov 18, 2019

Primary completion

Nov 1, 2024

Study completion Nov 1, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label extension study of voxelotor for participants with Sickle Cell Disease who have participated in voxelotor clinical trials.

Conditions

  • Sickle Cell Disease

Interventions

  • VoxelotorDrug

    All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a powder for oral suspension formulation (powder formulation packaged as stick packs).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (AEs)Time frame: From date of informed consent until 28 days after last dose of study drug (maximum up to 4.31 years)
  2. Number of Participants With SAEsTime frame: From date of informed consent until 28 days after last dose of study drug (maximum up to 4.31 years)
  3. Number of Participants With Sickle Cell Disease (SCD) Related TEAEs and SAEsTime frame: From date of informed consent until 28 days after last dose of study drug (maximum up to 4.31 years)

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Children's Healthcare of Atlanta Scottish Rite

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Children's Mercy Hospital

    Kansas City, Missouri

  • ECU Physicians, Brody Outpatient Clinic

    Greenville, North Carolina

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Alexandria University Hospital - Clinical Research Center

    Alexandria, Egypt

  • Cairo University Hospital, Abu El Rish Hospital

    Cairo, Egypt

  • Ain Shams University Hospital - Clinical Research Center (MASRI-CRC)

    Cairo, Egypt

  • Zagazig University Hospital

    Zagazig, Alsharkia, Egypt

  • American University of Beirut - Medical Center

    Beirut, Lebanon

  • Nini Hospital

    Tripoli, Lebanon

  • Barau Dikko Teaching Hospital/Kaduna State University

    Kaduna, Nigeria

  • Aminu Kano Teaching Hospital

    Kano, Nigeria

  • Lagos University Teaching Hospital

    Lagos, Nigeria

  • University of Calabar Teaching Hospital

    Calabar, Cross River State, Nigeria

  • College of Medicine, University of Ibadan

    Ibadan, Oyo State, Nigeria

  • Barts Health NHS Trust , The Royal London Hospital

    London, United Kingdom

  • Guy'S and St Thomas' Nhs Foundation Trust

    London, United Kingdom

  • University College Hospital NHS Foundation Trust

    London, Greater London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.